



Heart Failure: Crossing the Translational Divide

January 14–18, 2018 | Keystone Resort | Keystone, Colorado | USA

Scientific Organizers:

Yibin Wang, University of California, Los Angeles, USA

Joseph A. Hill, University of Texas Southwestern Medical Center, USA

Carolyn Lam, Duke-NUS Medical School, Singapore

Heart failure is a major human disease that afflicts millions of people worldwide. Intensive research in the past decade has yielded many exciting new mechanistic insights into the pathogenesis of heart failure, but progress toward successful therapies to prevent, halt and reverse heart failure has been painfully slow. The overall goal of this Keystone Symposia conference is to focus on heart failure and highlight the scientific advances in basic discovery and early-phase therapeutic development in this fast-moving field. The symposium will provide the field with an opportunity for robust discussion about the major issues crossing the translational divide from basic discovery to therapies.



Session Topics:

- HFrEF: Ischemic Heart Disease (I/R Injury and Cell Death)
- Inflammation (Non-Ischemic) HFrEF
- HFrEF: Hypertensive Heart Disease (Hypertrophy, Fibrosis)
- Workshop 1: Big Data and Precision Medicine for Heart Failure
- PH and RV Failure
- HFrEF and Metabolism
- Workshop 2: Pharma for HF, How NOT to Get Lost in Translation
- HFrEF: Genetics and Epigenetics
- HFpEF (Mechanisms and Therapy)
- HFrEF (Cellular and Molecular Therapy)

Scholarship Application & Discounted Abstract Deadline: September 21, 2017

Abstract Deadline: October 19, 2017

Discounted Registration Deadline: November 20, 2017



Note: Scholarships are available for graduate students and postdoctoral fellows and are awarded based on the abstract submitted. Submitting an abstract is an excellent opportunity to gain exposure for your work. Abstracts submitted by the abstract deadline will also be considered for short talks on the program.

Meeting Hashtag: #KShf

www.keystonesymposia.org/18A1

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230

a 501(c)(3) nonprofit educational organization

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Heart Failure: Crossing the Translational Divide (A1)

January 14-18, 2018 • Keystone Resort • Keystone, Colorado, USA

Scientific Organizers: Yibin Wang, Joseph A. Hill and Carolyn Lam

Sponsored by Amgen Inc.

Abstract & Scholarship Deadline: September 21, 2017 / Abstract Deadline: October 19, 2017 / Discounted Registration Deadline: November 20, 2017

SUNDAY, JANUARY 14

Arrival and Registration

MONDAY, JANUARY 15

Welcome and Keynote Address

David C. Page, Whitehead Institute for Biomedical Research, USA
Sex and Disease: Do Males and Females Read their Genomes Differently?

HFrEF: Ischemic Heart Disease (I/R Injury and Cell Death)

Laura Mauri, Brigham and Women's Hospital, USA
What Ischemic HFrEF Looks like Clinically and What I Wish I Had in My Toolbox

Richard N. Kitsis, Albert Einstein College of Medicine, USA
Understanding and Therapeutically Manipulating Cell Death in the Heart

Junichi Sadoshima, Rutgers New Jersey Medical School, USA
Autosis Mediates Myocardial Cell Death during Ischemia/Reperfusion

Workshop 1: Does an X or Y Make a Difference for the Heart?

***Joseph A. Hill**, University of Texas Southwestern Medical Center, USA

David C. Page, Whitehead Institute for Biomedical Research, USA
Translate Mechanism to Practice: for Sex Differences in HF

Mansoureh Eghbali, University of California, Los Angeles, USA
Sex Hormone or Sex Chromosome: The Real Culprit in Cardiac Injury and Dysfunction

***Vera Regitz-Zagrosek**, Charité - University Medicine Berlin, Germany
Translational Aspects of Sex Differences in Myocardial Ischemia and Hypertrophy

Carolyn Lam, Duke-NUS Medical School, Singapore
Sex Differences in HF-Clinical Trial

Inflammation (Non-Ischemic) HFrEF

Douglas L. Mann, Washington University School of Medicine, USA
What Inflammatory Cardiomyopathy Looks like Clinically and What I Wish I Had in My Toolbox

Peter Liu, Toronto Hospital, Canada
Talk Title to be Announced

Hongliang Li, Wuhan University, China
Novel Role of Innate Inflammatory Genes in Heart Disease

Poster Session 1

TUESDAY, JANUARY 16

HFrEF: Hypertensive Heart Disease (Hypertrophy, Fibrosis)

Joseph A. Hill, University of Texas Southwestern Medical Center, USA
What Hypertensive HFrEF Looks Like and What I Wish I Had in my Toolbox

Jeffery D. Molkenin, Cincinnati Children's Hospital Medical Center, USA

Fibroblast Dynamics in the MI Injured Heart

Mark E. Anderson, Johns Hopkins University School of Medicine, USA

CaMKII as a Therapeutic Target in Heart Failure and Arrhythmias

Timothy A. McKinsey, University of Colorado Denver, USA
Epigenetic Regulation of Heart Failure

Workshop 2: Big Data and Precision Medicine for Heart Failure

Peipei Ping, University of California, Los Angeles, USA
NHLBI Big Data to Knowledge

Elizabeth M. McNally, Northwestern University, USA
Genomic Solutions to Precision Medicine

Daniel P. Kelly, University of Pennsylvania, USA
Integrated Profiling Approaches to Delineating the Metabolic Origins of Heart Failure

PH and RV Failure

Mardi I. Gomberg-Maitland, Inova Heart and Vascular Institute, USA
Clinical Right Ventricular Failure and Pulmonary Hypertension: Mechanism, Clinical Phenotypes, and Statistical/Translational Treatment Approaches

Stephan Rosenkranz, Klinik III für Innere Medizin, Germany
Novel Targets in Pulmonary Vascular Disease and RV Dysfunction

Mansoureh Eghbali, University of California, Los Angeles, USA
Role of Oxidized Lipids in PH and RV Failure

Poster Session 2

WEDNESDAY, JANUARY 17

HFrEF and Metabolism

E. Dale Abel, University of Iowa, Carver College of Medicine, USA
Mitochondrial Metabolism and Signaling Mechanisms in Heart Failure

Peipei Ping, University of California, Los Angeles, USA
Uncovering Medical Insights from Vast Amounts of Biomedical Data in Clinical Case Reports

Daniel P. Kelly, University of Pennsylvania, USA
Mitochondrial Remodeling in Heart Failure

Rong Tian, University of Washington, USA
Metabolic Modulation of Cardiac Hypertrophy

Workshop 3: Pharma for HF, How NOT to Get Lost in Translation

Anthony J. Muslin, Sanofi, USA

HFrEF: Genetics and Epigenetics

Elizabeth M. McNally, Northwestern University, USA
How Genetics Informs the Care of HF

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Heart Failure: Crossing the Translational Divide (A1)

January 14-18, 2018 • Keystone Resort • Keystone, Colorado, USA

Scientific Organizers: Yibin Wang, Joseph A. Hill and Carolyn Lam

Sponsored by Amgen Inc.

Abstract & Scholarship Deadline: September 21, 2017 / Abstract Deadline: October 19, 2017 / Discounted Registration Deadline: November 20, 2017

Christine E. Seidman, Harvard Medical School, USA
Genetics of Cardiomyopathy: Insights into Cardiac Physiology and Disease

Thomas Thum, Medical School Hannover, Germany
Noncoding RNAs and Other Therapeutic Approaches in Cardiac Remodeling

Poster Session 3

THURSDAY, JANUARY 18

Keynote Address

***Carolyn Lam**, Duke-NUS Medical School, Singapore

Daria Mochly-Rosen, Stanford University, USA
Cardiac Disease: Crossing the Translational Divide

HFpEF (Mechanisms and Therapy)

David A. Kass, Johns Hopkins Hospital, USA
Dissecting Mechanisms of HFpEF - A Multiscale Approach

Carolyn Lam, Duke-NUS Medical School, Singapore
HFpEF Exists -- We Just Don't Know What to Call It

Wolfgang A. Linke, University of Munster, Germany
Targeting Cardiomyocyte Structure and Function in HFpEF

HFrEF (Cellular and Molecular Therapy)

Roger J. Hajjar, Mount Sinai School of Medicine, USA
Gene Therapy for Heart Failure & Pulmonary Hypertension

Hesham A. Sadek, University of Texas Southwestern Medical Center, USA
Rethinking the Effect of Hypoxia on Cardiomyocytes

Joseph C. Wu, Stanford University School of Medicine, USA
Genomics and Stem Cells for Precision Cardiovascular Medicine

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, JANUARY 19

Departure